Market Data 
Markets
Replies to post #732782 on NorthWest Biotherapeutics Inc (NWBO)
11/18/24 2:28 PM
To determine which dendritic cell (DC) vaccine is being used in the study you referenced, I'll evaluate the key details and process described in the article (freeze/thaw cycle, broad antigen presentation, tumor lysate approach) and compare them to known DC vaccines.
Process from the Article:
Freeze/Thaw Cycle:
This is a method to process tumor tissue to release a broad spectrum of tumor antigens.
Broad Antigen Presentation:
The focus appears to be on presenting multiple antigens rather than pre-selecting specific ones.
Autologous Tumor Lysate:
Implies the vaccine uses the patient's own tumor tissue to create a personalized antigen source.
Key Comparison:
DCVax-L (Northwest Biotherapeutics):
Uses autologous tumor lysate, processed via a freeze/thaw cycle.
Presents a broad spectrum of antigens to the immune system.
Specifically developed for glioblastoma but is adaptable to other cancers.
Matches the process described in the article closely.
ICT-107 (ImmunoCellular Therapeutics):
Uses pre-selected synthetic peptides rather than tumor lysate.
Targets specific antigens like HER2 and gp100, not a broad antigen spectrum.
Less likely to match the described process.
Neoantigen-Based DC Vaccines:
Focus on personalized neoantigens derived from sequencing the tumor's unique mutations.
Do not typically use a freeze/thaw cycle or tumor lysate.
Process differs significantly from the article's description.
DC vaccines using allogeneic tumor lysates:
Employ lysates from tumor cell lines, not the patient's tumor.
May use a freeze/thaw process but lack the personalized approach of autologous lysate.
Some overlap in method, but less likely given the focus on individual tumors.
DCVax-Direct:
Similar approach to DCVax-L but involves injecting dendritic cells directly into the tumor.
Process doesn't rely on ex vivo preparation with tumor lysate.
Unlikely to be the vaccine in question.
Odds and Analysis:
Given the description of the process in the article (freeze/thaw cycle, broad antigen presentation, autologous tumor lysate), DCVax-L is by far the closest match. Its established methodology aligns almost identically with the described vaccine's preparation and function.
Likelihood assessment:
DCVax-L: 90%
ICT-107: 5%
Neoantigen-Based DC Vaccines: 3%
Allogeneic Tumor Lysate DC Vaccines: 2%
DCVax-Direct: <1%
The process strongly suggests DCVax-L or a very similar vaccine employing autologous tumor lysate and freeze/thaw methods to present multiple tumor antigens. If this is not DCVax-L, it is highly likely inspired by its methodology.
AI
